日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia

治疗前外周血T细胞受体克隆性高可预测免疫性血小板减少症的长期疗效

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.70310
Schmidt-Barbo, Paul; Schultheiss, Christoph; Jauch, Annaïse J; Simnica, Donjetë; Silling, Gerda; Hänel, Mathias; Chromik, Jörg; Stauch, Thomas; Trautmann-Grill, Karolin; Repp, Roland; Schulte, Clemens; Fleischmann, Bastian; Welslau, Manfred; Stauch, Martina; Quiering, Claudia; Richter, Frank; Tesanovic, Tamara; Jahn, Sabine; Holbro, Andreas; Passweg, Jakob R; Matzdorff, Axel; Rummel, Mathias; Meyer, Oliver; Nimmerjahn, Falk; Binder, Mascha
血小板
T细胞
信号转导
T细胞
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial

雷珠单抗与阿柏西普治疗新生血管性年龄相关性黄斑变性（SALT）对视网膜厚度波动的影响：一项多中心、随机、IV期试验的12个月结果

期刊:British Journal of Ophthalmology
影响因子:3.5
doi:10.1136/bjo-2024-326526
Agostini, Hansjuergen T; Silva, Rufino; Holz, Frank G; Larsen, Michael; Altay, Lebriz; Souied, Eric H; Quiering, Claudia; Rose, Uwe; Liakopoulos, Sandra
发表日期：2025
文献求助 收藏

The Endocrine Treatment Landscape for Patients with HR+ HER2- Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy - A Real-World Analysis

在 CDK4/6 抑制剂疗法引入之前，德国 HR+ HER2- 早期乳腺癌患者的内分泌治疗现状——一项真实世界分析

期刊:Geburtshilfe Und Frauenheilkunde
影响因子:1.9
doi:10.1055/a-2100-0643
Nabieva, Naiba; Altmann, Falk; Apel, Klaus; Baerens, Dirk-Toralf; Beha, Michaela; Belau, Antje; Busch, Steffi; Guth, Dagmar; Heinrich, Georg; Kreiss-Sender, Janine; Markmann, Susanne; Olbermann, Andreas; Oskay-Özcelik, Gülten; Schuback, Beatrix; Steinfeld-Birg, Dieter; Quiering, Claudia; Kiss, Ferenc; Kreuzeder, Julia; Nuti, Paolo; Schilling, Jörg
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2023
文献求助 收藏

A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study

一项随机、开放标签、多中心研究，旨在评估对解剖结构控制欠佳的新生血管性年龄相关性黄斑变性患者，改用brolucizumab治疗（无论是否给予负荷剂量）的疗效——FALCON研究

期刊:Graefes Archive for Clinical and Experimental Ophthalmology
影响因子:2.3
doi:10.1007/s00417-022-05591-z
Holz, F G; Schmitz-Valckenberg, Steffen; Wolf, A; Agostini, H; Lorenz, K; Pielen, A; Feltgen, N; Guthoff, R; Quiering, C; Clemens, A; Jaeger, K
发表日期：2022
文献求助 收藏

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial

依维莫司联合依西美坦治疗激素受体阳性、人表皮生长因子受体2阴性的绝经后局部晚期或转移性乳腺癌患者的疗效和安全性：单臂IIIB期4EVER试验结果

期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.31738
Tesch, Hans; Stoetzer, Oliver; Decker, Thomas; Kurbacher, Christian M; Marmé, Frederik; Schneeweiss, Andreas; Mundhenke, Christoph; Distelrath, Andrea; Fasching, Peter A; Lux, Michael P; Lüftner, Diana; Hadji, Peyman; Janni, Wolfgang; Muth, Mathias; Kreuzeder, Julia; Quiering, Claudia; Taran, Florin-Andrei
肿瘤
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2019
文献求助 收藏

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

在 IIIb 期 4EVER 试验中，哺乳动物雷帕霉素靶蛋白抑制剂对接受依维莫司联合依西美坦治疗的激素受体阳性绝经后晚期乳腺癌女性骨骼健康的影响

期刊:Journal of Bone Oncology
影响因子:3.5
doi:10.1016/j.jbo.2018.09.010
Hadji, Peyman; Stoetzer, Oliver; Decker, Thomas; Kurbacher, Christian M; Marmé, Frederik; Schneeweiss, Andreas; Mundhenke, Christoph; Distelrath, Andrea; Fasching, Peter A; Lux, Michael P; Lüftner, Diana; Janni, Wolfgang; Muth, Mathias; Kreuzeder, Julia; Quiering, Claudia; Grischke, Eva-Marie; Tesch, Hans
肿瘤
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2019
文献求助 收藏